Cadila Healthcare Lupin
It is unlikely for Zydus Cadila to repeat US feat this year, say analysts
Analysts doubt if other Indian firms in the segment will do much better in the formulations business in the US
 "It is unlikely for Zydus Cadila to repeat US feat this year, say analysts")
Updated On : 19 Jul 2019 | 12:07 AM IST
Cadila Healthcare surpasses Lupin to become 2nd most valuable pharma firm
Cadila Healthcare with m-cap of Rs 54,719 cr, stood ahead of Lupin, which have m-cap of Rs 52,217 cr
 "Cadila Healthcare surpasses Lupin to become 2nd most valuable pharma firm")
Updated On : 08 Jun 2017 | 1:10 AM IST
